Oric Pharmaceuticals Inc ( (ORIC) ) has released its Q1 earnings. Here is a breakdown of the information Oric Pharmaceuticals Inc presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments to overcome resistance in cancer, with its primary operations based in South San Francisco and San Diego, California. In its first quarter of 2025, ORIC Pharmaceuticals reported significant advancements in its clinical programs, particularly for its lead candidates ORIC-944 and ORIC-114, while also extending its financial runway into 2027. The company highlighted promising preclinical data for ORIC-944 in prostate cancer and announced a collaboration with Johnson & Johnson to explore ORIC-114 in lung cancer treatment. Financially, ORIC ended the quarter with $224 million in cash and investments, with increased R&D and G&A expenses compared to the previous year, reflecting its ongoing development efforts. Looking forward, ORIC Pharmaceuticals anticipates multiple data readouts over the next 15 months and plans to initiate Phase 3 trials for its lead programs in 2026, aiming to further its mission of addressing therapeutic resistance in cancer.